Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syros Pharmaceuticals
(NQ:
SYRS
)
5.140
+0.150 (+3.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Syros Pharmaceuticals
< Previous
1
2
3
Next >
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
April 09, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
March 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
March 25, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
March 20, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
January 08, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 19, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
December 06, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in Upcoming Investor Conferences
November 21, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 14, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
October 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 08, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
August 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Sidoti Events, LLC's Virtual June Small-Cap Conference
June 13, 2023
Via
ACCESSWIRE
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
June 08, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
May 25, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
May 10, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Present at JMP Securities 2023 Life Sciences Conference
May 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 03, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
March 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in Upcoming Investor Conferences in March
February 28, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
February 23, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.